Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
Regulatory watch: Innovative drug availability in China
TLDR
The availability in China of new drugs approved by the US Food and Drug Administration during 2004–2014 was investigated and it was found that several innovative cancer drugs were approved in China more than 10 years after its initial approval in the United States.
View on Nature
Public- and Private-Sector Contributions to the Research and Development of the Most Transformational Drugs in the Past 25 Years
TLDR
Industry’s contributions to the R&D of innovative drugs go beyond development and marketing and include basic and applied science, discovery technologies, and manufacturing protocols, and that without private investment in the applied sciences there would be no return on public investment in basic science.
View on SAGE
Market watch: Where is personalized medicine in industry heading?
View on Nature
Market watch: Landscape for medical countermeasure development
TLDR
The most substantial change in the landscape in the time-frame of the CSDD analyses is the size of the MCM pipeline, which grew to 592 in 2016.
View on Nature
Competitive Development in Pharmacologic Classes: Market Entry and the Timing of Development
TLDR
Data on the entry rates of second and later entrants in 43 pharmacologic classes, as well as the timing of patent filings and development milestones for 79 later‐in‐class drugs, found that a substantial majority of later-in‐ class drugs had a patent filed and were in clinical development prior to the approval of the first‐in-class drug.
View on Wiley
Impact of Postapproval Evidence Generation on the Biopharmaceutical Industry.
View on PubMed
Restricting access to florbetapir: Medicare coverage criteria for diagnostics and drugs are inconsistent
Medicare’s decision to restrict coverage of florbetapir, a diagnostic agent for Alzheimer’s disease, exemplifies an inconsistent approach to technology evaluation. Joshua Cohen and colleagues call…
View on BMJ
State of the industry for drug-diagnostic development: challenge and change on the path to precision medicine.
TLDR
It was found that even with payer pushback and adjusting to new business models, the majority of developers expected their business to increase over the next 5 years, and several factors that unexpectedly helped to shape the personalized medicine landscape.
View on PubMed
Public and Private Sector Contributions to the Research & Development of the Most Transformational Drugs of the Last 25 Years
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License